M
US self-pay prices

Maximus GLP-1 prices

Telehealth

Men's health telehealth selling brand-name Wegovy, Zepbound, Foundayo, Ozempic and Mounjaro at one monthly price per dose with no membership fee, and compounded tirzepatide on 2- to 12-month plans. Maximus has 8 sourced self-pay GLP-1 offers here. Advertised entry prices: Compounded tirzepatide $249.99/mo; Foundayo $299.99/mo; Mounjaro pen $1,349.99/mo; Ozempic pen $449.99/mo; Wegovy HD pen (7.2 mg) $649.99/mo; Wegovy pen $449.99/mo; Wegovy pill $349.99/mo; Zepbound KwikPen $549.99/mo. Compounded products are not FDA-approved. Plan terms, fees and the check date are listed with each quote.

Tirzepatide · Compounded

1 offers · US self-pay

This order ignores commission. Partner links may earn us a referral fee.

  • Compounded tirzepatide via Maximus

    Tirzepatide · Compounded

    Compounded · Not FDA-approved
    Advertised price$249.99/mo

    2-month upfront payment required

    Supply period unverified; excluded from cost ranking.

    Checked

    Maintenance price

    No separate dose price verified

    View offer
    Price conditions & source

    Advertised price: 2-month plan billed upfront for the term; $219.99/mo on 4 months, $199.99 on 6, $149.99 on 12; one flat rate at every dose; renews at the same rate unless cancelled; no membership fees

    Ships every 2 months. Not available in Alabama, Mississippi or Louisiana. Compounded; not FDA-approved.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.

    Read the advertised-price source

Read prices in context. Compare the same product, dose, and payment terms. A prepaid monthly rate is not a monthly payment. Cost order uses current, recently checked quotes with documented supply periods, converted to 30 days. Other prices are unranked references. Dose changes, introductory terms and added fees affect what you pay.

Missing prices are not estimated. A listed maintenance dose is not a dosing recommendation.

The FDA declared the tirzepatide (December 2024) and semaglutide (February 2025) shortages resolved, ending the exemption that let pharmacies mass-produce compounded copies, and the 503A/503B enforcement-discretion grace periods ended in 2025. The FDA is now actively enforcing (warning letters and takedowns, including a September 2026 warning letter to Empower Pharmacy, a large compounder, over products it called essentially copies of approved semaglutide and tirzepatide), and in 2026 proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list (the public comment period, extended 30 days, closed July 30, 2026; a final decision is pending). Liraglutide is different: it is still on the FDA drug shortage list (brand Victoza and Saxenda in limited supply, generics available, as of September 2026). Compounded GLP-1s are not FDA-approved and are now generally limited to narrow, patient-specific 503A prescriptions, so broad low-cost availability has largely wound down. They also carry safety risks the branded products do not: FDA adverse-event reports, at least one sterility recall (ProRx, October 2025), and counterfeit product found in the US supply chain, so a low price is not a low-risk signal. Prices and availability below may lag these changes; confirm current terms with the provider.

Some outbound links on GLPcompare are referral links. If you sign up or buy through one, we may earn a commission at no extra cost to you. It never changes the price you pay or the underlying data. Partner status and commission rates contribute to offer and provider value scores and can change their order. Every partner is labeled. Value scores are not medical recommendations; a higher-ranked offer is not necessarily the lowest price or the right product for you.

Maximus microdose plans

Low-dose plans Maximus sells apart from its regular plans. They are compounded, not FDA-approved, and priced for a dose below the maintenance doses on the FDA labels.

  • Microdose semaglutide: $99.99/mo. Starting dose 0.25 mg weekly; physician-supervised; compounded and shipped from a licensed U.S. pharmacy. Maximus calls low-dose use an off-label use and says its microdosing protocol is not a weight-loss protocol. Checked Oct 19, 2026, source (Maximus microdose price source).
  • Microdose tirzepatide: $132.99/mo. Starting dose 1.5 mg weekly; physician-supervised; compounded and shipped from a licensed U.S. pharmacy. Maximus calls low-dose use an off-label use and says its microdosing protocol is not a weight-loss protocol. Checked Oct 19, 2026, source (Maximus microdose price source).Regular plan: $249.99/mo.
Compare microdose prices at every seller
Questions

Maximus GLP-1 cost: common questions

How much does tirzepatide cost through Maximus?

Compounded tirzepatide: $249.99/mo (2-month plan billed upfront for the term; $219.99/mo on 4 months, $199.99 on 6, $149.99 on 12; one flat rate at every dose; renews at the same rate unless cancelled; no membership fees). Mounjaro pen: $1,349.99/mo (ongoing monthly price at every listed dose (2.5 to 12.5 mg); $1,249.99 the first month; no membership fee). Zepbound KwikPen: $549.99/mo (ongoing monthly price at 2.5 mg; $449.99 the first month; no membership fee); $749.99/mo at 15 mg. Checked Oct 16, 2026; each quote links its source in the table. Compounded tirzepatide is not an FDA-approved product.

How much does orforglipron cost through Maximus?

Foundayo: $299.99/mo (ongoing monthly price at 0.8 mg; $199.99 the first month; no membership fee); $499.99/mo at 17.2 mg. Checked Oct 16, 2026; each quote links its source in the table.

How much does semaglutide cost through Maximus?

Ozempic pen: $449.99/mo (ongoing monthly price at 0.25 mg; $349.99 the first month; no membership fee); $799.99/mo at 2 mg. Wegovy HD pen (7.2 mg): $649.99/mo (ongoing monthly price at 7.2 mg; $549.99 the first month; no membership fee). Wegovy pen: $449.99/mo (ongoing monthly price at 0.25 and 0.5 mg; $349.99 the first month; no membership fee); $599.99/mo at 2.4 mg. Wegovy pill: $349.99/mo (ongoing monthly price at 1.5 and 4 mg; $249.99 the first month; no membership fee); $499.99/mo at 25 mg. Checked Oct 16, 2026; each quote links its source in the table.

Does Maximus offer FDA-approved GLP-1 medication or compounded versions?

Both are tracked here. FDA-approved products: Foundayo; Mounjaro pen; Ozempic pen; Wegovy HD pen (7.2 mg); Wegovy pen; Wegovy pill; Zepbound KwikPen. Compounded: Compounded tirzepatide. Compounded GLP-1s are not FDA-approved products and are not reviewed by the FDA for safety, effectiveness, or quality.

When were Maximus prices last checked?

Each quote carries its own check date and links the page it was read from: Oct 16, 2026 for the offers here. A quote not rechecked within 21 days is kept as a dated reference and is no longer stated as a current price.

How much does Maximus' microdose GLP-1 cost?

Maximus' microdose semaglutide: $99.99/mo. Starting dose 0.25 mg weekly; physician-supervised; compounded and shipped from a licensed U.S. pharmacy. Maximus calls low-dose use an off-label use and says its microdosing protocol is not a weight-loss protocol. Checked Oct 19, 2026. Maximus' microdose tirzepatide: $132.99/mo. Starting dose 1.5 mg weekly; physician-supervised; compounded and shipped from a licensed U.S. pharmacy. Maximus calls low-dose use an off-label use and says its microdosing protocol is not a weight-loss protocol. By comparison, its regular compounded tirzepatide plan is $249.99/mo. Checked Oct 19, 2026. Microdose GLP-1 prices at every seller

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.